Timothy Dutta
Cardiovascular Disease · New York, NYNPI 1992752885
Payments from drug & device makers
Across 184 payments — averaging $16.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Amgen$685
- Intercept Pharmaceuticals, Inc.$187
- Novo Nordisk$172
- Regeneron Healthcare Solutions, Inc.$163
- AbbVie$160
- plus $634 from 14 others
What the payments were for
- Food & beverage$3,060100%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 62 | $1,070 |
| Amgen | 54 | $685 |
| Intercept Pharmaceuticals, Inc. | 8 | $187 |
| Novo Nordisk | 12 | $172 |
| Regeneron Healthcare Solutions, Inc. | 7 | $163 |
| AbbVie | 8 | $160 |
| Boston Scientific | 5 | $120 |
| Daiichi Sankyo Inc. | 5 | $110 |
| GSK | 5 | $87 |
| Genentech USA, Inc. | 4 | $70 |
| Nestle Healthcare Nutrition Inc. | 2 | $39 |
| Novartis | 2 | $35 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| Eisai Inc. | 1 | $25 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $24 |
| Philips North America LLC | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $18 |
| Braintree Laboratories, Inc. | 1 | $17 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
How this compares
$3,071 in reported general payments places this provider in the 60th percentile of 2,302 cardiovascular disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $400,382 |
| XareltoRivaroxaban | 117 | $131,503 |
| Repatha SureclickEvolocumab | 88 | $95,847 |
| Praluent PenAlirocumab | 65 | $49,315 |
| JardianceEmpagliflozin | 22 | $27,973 |
| EntrestoSacubitril/Valsartan | 17 | $23,316 |
| JanuviaSitagliptin Phosphate | 13 | $18,504 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $9,058 |
| Atorvastatin Calcium | 583 | $6,737 |
| Rosuvastatin Calcium | 369 | $6,116 |
| Ezetimibe | 207 | $5,809 |
| SynthroidLevothyroxine Sodium | 50 | $5,503 |
| Digoxin | 45 | $4,451 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 80 | $3,980 |
| Metoprolol Succinate | 218 | $3,602 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $35 | $23,31617 claims |
| GSKBreo Ellipta | $87 | $9,05824 claims |
| AbbVieSynthroid | $160 | $5,50350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,302 cardiovascular disease providers in New York.
Other cardiovascular disease in New York
- James MinNew York$41.1M
- Robert RosensonNew York$6.9M
- Roxana MehranNew York$6.4M
- Roger HajjarNew York$5.2M
- Philippe GenereuxNew York$4.4M
- Gregg StoneNew York$3.7M
- Valentin FusterNew York$2.9M
- Tamim NazifNew York$2.2M
- Howard WeintraubNew York$1.7M
- Anuradha Lala-TrindadeNew York$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.